Retatrutide for Fat Loss
The 'Godzilla' of weight loss; a triple-hormone agonist for unprecedented fat loss and metabolic health.
Why Retatrutide for fat loss?
Retatrutide is an investigational triple agonist developed by Eli Lilly. It mimics GLP-1, GIP, and glucagon, leading to significant improvements in weight, glycemic control, and liver health.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Retatrutide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Unrivaled weight loss (up to 24%+)
- Reverses liver fat (80%+ reduction)
- Reduces visceral fat
Reference dosing by bodyweight
Anchored to the most-cited research dose (2000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 1247–1687 mcg |
| 60–75 kg / 132–165 lb | 1530–2070 mcg |
| 75–90 kg / 165–198 lb | 1870–2530 mcg |
| 90–105 kg / 198–231 lb | 2210–2990 mcg |
| >105 kg / >231 lb | 2550–3450 mcg |
Side effects to weigh against fat loss benefit
- Nausea
- Diarrhea
- Vomiting
- Increased heart rate (mild)
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.